Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Draft Bill Adds $70 Mil. For Rx Safety To User Fee Totals; Mark-Up Looms

Executive Summary

A draft of the bill to reauthorize FDA's user fee program would add $70 million to the total fee negotiated by the agency and industry in order to pay for additional Rx safety oversight

You may also be interested in...



Adverse Event Hotline On Rx Bottles Gets Final Rule; No Enforcement Till 2009

As mandated by the FDA Amendments Act, a rule that requires Rx packaging to contain a toll-free number for reporting adverse events is now in effect, but FDA said it will not likely enforce it until 2009

Adverse Event Hotline On Rx Bottles Gets Final Rule; No Enforcement Till 2009

As mandated by the FDA Amendments Act, a rule that requires Rx packaging to contain a toll-free number for reporting adverse events is now in effect, but FDA said it will not likely enforce it until 2009

FDA Putting System In Place For RiskMAP Evaluation And Management

FDA is trying to provide clarity on its risk management plan program by creating a Web site that will serve as a central source of risk management plan information

Related Content

UsernamePublicRestriction

Register

PS048258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel